Clinical trials
Dyspnea trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 10 |
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
| Unknown status | 9 |
| Recruiting | 7 |
| Terminated | 4 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| King's College Hospital NHS Trust | 4 |
| Cambridge University Hospitals NHS Foundation Trust | 3 |
| Oxford Brookes University | 2 |
| Royal Brompton & Harefield NHS Foundation Trust | 2 |
| TidalSense | 2 |
| University of Oxford | 2 |
| Alisa Apreleva | 1 |
| AstraZeneca | 1 |
| Bournemouth University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dyspnea | 51 |
| Pulmonary Disease, Chronic Obstructive | 16 |
| Asthma | 12 |
| Heart Failure | 7 |
| Cough | 6 |
| Anxiety Disorders | 4 |
| Lung Diseases, Interstitial | 4 |
| Lung Neoplasms | 4 |
| Disease | 3 |
| Idiopathic Pulmonary Fibrosis | 3 |
Trials
Showing 1 to 25 of 51. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.